Immune checkpoint blockade in cancer immunotherapy: mechanisms, clinical outcomes, and safety profiles of PD-1/PD-L1 inhibitors

• Autorzy: Yan Y. , Zhang L. , Zuo Y. , Qian H. , Liu C.
• Języki publikacji: EN

Abstrakty

EN

Słowa kluczowe

EN

cancer immunotherapy; tumour cell; colorectal cancer; monoclonal antibody; regulatory T cell; antigen-presenting cell; interferon gamma; tumour necrosis factor-alpha; interleukin 2; dendritic cell; major histocompatibility complex

• Wydawca: -
• Czasopismo: Archivum Immunologiae et Therapiae Experimentalis
• Rocznik: 2020
• Tom: 68
• Numer: 6
• Opis fizyczny: Article 36 [15p.], fig.,ref.

Twórcy

autor

Yan Y.

• The Affiliated Zhangjiagang Hospital of Soochow University, Zhangjiagang, 215600, Jiangsu, People’s Republic of China

autor

Zhang L.

• Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, People’s Republic of China
• College of Pharmacy, University of South Carolina, Columbia, SC, 29208, USA

autor

Zuo Y.

• The Affiliated Zhangjiagang Hospital of Soochow University, Zhangjiagang, 215600, Jiangsu, People’s Republic of China

autor

Qian H.

• The Affiliated Zhangjiagang Hospital of Soochow University, Zhangjiagang, 215600, Jiangsu, People’s Republic of China

autor

Liu C.

• College of Pharmacy, University of Rhode Island, Kingston, RI, 02881, USA

Identyfikatory

DOI

10.1007/s00005-020-00601-6